Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Date:12/10/2007

Dr. Paul Richardson presents Phase 1 results demonstrating clinical

activity of perifosine in combination with bortezomib in patients previously treated with bortezomib, and provides an update on an ongoing

Phase 2 study of perifosine in combination with dexamethasone

NEW YORK, Dec. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that positive phase 1 & phase 2 data of perifosine (KRX-0401) in patients with advanced, relapsed/refractory multiple myeloma (MM) were presented on Saturday, December 8, 2007 at the 49th Annual Meeting of the American Society of Hematology. In two separate poster presentations, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI) in Boston, MA, provided the phase 1 results on the clinical activity of perifosine in combination with Bortezomib, and an update on an ongoing phase 2 study of perifosine in combination with dexamethasone.

Phase 1 Perifosine + VELCADE(R) (Vel)

Poster 324-I: A MULTICENTER PHASE 1/2 TRIAL OF PERIFOSINE (KRX-0401) + BORTEZOMIB IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB: PHASE I RESULTS

Eighteen patients (median age 64 yrs) with advanced MM (83% relapsed and refractory) were enrolled in one of four cohorts. Patients had a median of 5 lines of prior therapy and 100% of patients were previously treated with at least one course of therapy on bortezomib. Perifosine was escalated from 50 to 100 mg qd while bortezomib was escalated from 1.0 to 1.3 mg/mm2. No dose- limiting toxicity and no grade 3 peripheral neuropathy were reported. Toxicities were generally well
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wire/--AccordingtoMillenniumResearchGroup(MRG),the...ce,thenearly$3billionUSmarketfortraumafixationdevi...sdespitetherecenteconomicslowdown.MRG,s USMarketsf...lremainhighlydynamicoverthenextfiveyears,withcompe...erservedsegmentsofthetraumafixationmarket,fuelingm...
(Date:11/25/2009)...-Reportlinker.comannouncesthatanewmarketresearchre...ugDelivery-USMarketTrends&Analysis http://www...y---US-Market-Trends--Analysis.html ,, TheUSin...ftherapeuticapplicationsfromthedeliveryofconventio...rapeuticdrugs.Thefutureofthetechnologyhingesontoth...
(Date:11/24/2009)...ire-Asia/--ChindexInternational,Inc.,("Chindex")(N...fWestern,healthcareproductsandservicesinthePeople,...attendthe21stAnnualPiperJaffray,"Unplugged"HealthC...rkPalaceHotel. , Managementiscurrentlyschedul...dholdone-on-onemeetingsthroughouttheday.Awebcast,o...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 1Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 3Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 4Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 5Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 1Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 2Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 3Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 4Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 58961 1Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 58961 2Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 58961 3
(Date:11/25/2009)...stress increase blood pressure? This simple quest...y years. New Stress-related gene Modulates High B... blood pressure? This simple question has been th...ew research has for the first time established a l... pressure response to stress in mice as well as hu...
(Date:11/25/2009)...ab, already used to fight rheumatoid arthritis, co... , WEDNESDAY, Nov. 25 (HealthDay News) --...oma and rheumatoid arthritis now also shows some p...pe 1 diabetes. , The drug, rituximab (Rituxan),...insulin, even though the disease had destroyed som...
(Date:11/25/2009)..., forgetfulness could lead mothers to overlook nee.... 25 (HealthDay News) -- A mother,s depression can...found. , Their six-month study of 262 black mot...mothers had more depressive symptoms had more freq...th fewer depressive symptoms had less frequent ast...
(Date:11/25/2009)... positive note, CDC sees few signs of trouble with...25 (HealthDay News) -- The ongoing H1N1 swine flu ...s pneumonias among younger patients, a U.S. health...ncrease in serious pneumococcal infections around ...ational Center for Immunization and Respiratory Di...
(Date:11/25/2009)... ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheA...tHealthCareFraudActof2009,"S.2128,whichisdesignedt...reventfraudinMedicare.ThebillwasintroducedbySen.Ge...everalprovisionstheAmericanAssociationforHomecareo...ssociationproposedtoCongressinFebruary.Thoseprovis...
Breaking Medicine News(10 mins):Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
... the meat, women go for the veggies , , WE...ary battle of the sexes, men are decidedly the car... new study finds. , Why the difference? Biology m...id L. Katz, director of the Prevention Research Ce...
...ers at the University of Pennsylvania School of Me...ed look at the molecular pathways underlying sleep...ricans, according to the National Institutes of He...ds of times a night. , The team found that in an...
...st Score in Comprehensive Report Comparing SSO and...Healthcare Industry, ANDOVER, Mass., March 19 Se...le Sign-On (SSO), announced today that it ranked #... Report (February, 2008) published by the healthca...
...ad scientific articles on drinking water treatment...this joint initiative of TU Delft and UNESCO-IHE i...ions, especially for researchers in developing cou...t ) journal for free; it is the author who pays fo...
... 19 In an Open,Letter to the Federal Drug Adminis...f the American Journal of Transplantation (AJT), t...he American Society of Transplant,Surgeons (ASTS) ...tter,s authors, described the letter as an appeal ...
...nd researchers will be at the forefront of fightin...he Australian Cancer Research Foundation (ACRF). ...s Diamantina Institute for Cancer, Immunology and ...s linked to cancer. , We will be able to sequenc...
Other Medicine News:Health News:The Gender Divide Starts Over Dinner 2Health News:The Gender Divide Starts Over Dinner 3Health News:Molecular biology of sleep apnea could lead to new treatments 2Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 2Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 3Health News:Free online scientific journal on drinking water 2
1-Day Acuvue
Magellan Mapper
Easygraph
Durasoft 3 Colors
Medicine Products: